权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Enteroviral 2C protein as a therapeutic target

肠道病毒2C蛋白作为治疗靶点

基本信息

批准号：
10609524
负责人：
CRAIG E. CAMERON
金额：
$ 74.79万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-04-13 至 2027-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10609524
关键词：
ATP phosphohydrolase Address Biochemical Biological Biological Models Biological Process Cell model Cells Chemicals Child Chimeric Proteins Code Collaborations Coxsackie Viruses Cytoplasm Data Dependence Development Drug resistance Electron Microscopy Enterovirus Enterovirus 68 Enterovirus 71 Enzymes Evolution Exhibits Fluorescence Microscopy Genetic Recombination Genome Guanidines Hela Cells Human Human poliovirus Hydantoins Infant Infection Institution Kinetics Laboratories Length Lipids Location Mass Spectrum Analysis Mediating Membrane Modeling Molecular Target Mutation Nucleotides Proteins Public Health Publishing RNA RNA-Directed RNA Polymerase Reporting Resistance Risk Role Scanning Serotyping Site Solubility Specificity Structure Transmission Electron Microscopy Tumor Cell Line Vesicle Virion Virulent Virus Virus Diseases biophysical properties biophysical techniques design dimer fitness graduate student helicase inhibitor lipidome member physical property therapeutic target viral RNA viral fitness

项目摘要

Project Abstract Non-polio human enteroviruses (NPEVs) represent an existing and emerging threat to public health, especially to infants and children. With more than 100 NPEVs known and the high rate of mutation and recombination of these viruses, the risk for evolution of virulent strains is high. Because we cannot predict the serotype of any newly emerging strain, addressing this problem effectively will require pan-enterovirus solutions. All NPEVs encode an enzyme, which has been termed 2C. This enzyme is as well conserved as the enterovirus RNA- dependent RNA polymerase (RdRp). Indeed, inhibitors of 2C with activity against multiple enteroviruses have been known for decades, with even more reported over the past few years alone. A major obstacle to further development of these compounds is the absence of an established experimental framework to define mechanism of action and to guide design of pan-enterovirus activity. Two of the earliest inhibitors of 2C: guanidine hydrochloride (GuHCl); and 5-(3,4-dichlorophenyl)- methylhydantoin (hydantoin), revealed roles for 2C both in genome replication and virion assembly. Because 2C protein is a member of helicase superfamily 3, the prevailing view has been that 2C is a hexameric helicase that cooperates with RdRp by unwinding RNA structure during genome replication and by facilitating genome encapsidation during virion assembly. Unfortunately, only indirect evidence exists to support these views. Nearly five years ago, our laboratory initiated an effort to connect the biochemical and biophysical properties of 2C to its biological functions using poliovirus (PV) as our model. The advances made to date, all unpublished, have changed the way we think about structure-dynamics-function relationships of 2C, the subcellular locations in which 2C manifests its virion-assembly function, and the physical properties of the virus-induced membranes with which 2C must interact during infection. In this application, we propose to add Enterovirus A71 (EV-A71), Coxsackievirus B3 (CVB3), and Enterovirus D68 (EV-D68) to our studies of PV to establish unifying models for the biological functions of 2C that will provide a framework to establish 2C as a pan-enterovirus therapeutic target. We will do so by pursuing the following specific aims: Elucidate the quaternary structure and kinetic mechanism of 2C ATPase (Aim 1); Elucidate the impact of drug resistance on 2C ATPase activity and viral fitness (Aim 2), and Characterize sites contributing to genome encapsidation (Aim 3).

项目摘要